Aim: Fluorescence in situ hybridization (FISH) is an important ancillary tool for the classification of bone/soft tissue (BST) tumors. The aim of this study was to evaluate the contribution of FISH to the final classification of common BST entities in the molecular pathology department of the Royal Prince Alfred Hospital (RPAH), which is one of the most important referral centers for the management of sarcomas in Australia.
INTRODUCTION
Bone and soft tissue (BST) pathology is one of the most challenging areas of diagnostic tissue pathology. The identification of defining chromosomal abnormalities in a number of BST tumors has provided the opportunity to utilize fluorescence in situ hybridization (FISH) as an ancillary tool to confirm morphological diagnoses and resolve diagnostic dilemmas. In fact, recent recommendations 2, 3 advise that confirmatory FISH be undertaken in newly diagnostic BST where a specific assay is available regardless of the certainty in the diagnosis. It is important to note that the lack of careful integration between the clinicopathological diagnosis and the FISH analysis can result in misdiagnosis and detrimental clinical outcomes. [4] [5] [6] The use of FISH has become an essential ancillary tool to assist in the diagnosis and classification of more than 50 BST tumors, which harbor recurrent tumor translocations or copy number changes as a defining diagnostic feature. 6, 7 In the diagnostic setting, the most commonly rearranged fusion genes identi-
fied by FISH include EWSR1, SS18, FUS, DDIT3, FUS, USP6 and PDGFB.
Assessment of MDM2 copy number is also employed in the classification of lipomatous, osseous and spindle cell lesions. 6, 7 FISH offers unique advantages over other molecular diagnostic tools. Chromosomal translocations produce specific gene fusions, which can be detected in formalin-fixed paraffin embedded (FFPE) tissue by in situ hybridization techniques and directly visualized within tumor cells. In contrast to cytogenetics, FISH does not require fresh tissue with subsequent culture of the neoplastic cells. While reverse transcription-polymerase chain reaction (RT-PCR) requires multiple primers to identify all possible rearrangements involving the specific breakpoint, in-situ hybridization probes are able to identify all known rearrangements involving a common breakpoint region of a given translocation. In addition, FISH also provides detailed cellular localization of the translocated gene unlike RT-PCR assays. 8, 9 This is particularly important in the assessment of tumors comprised of a mixed cell population in which only a subset of cells harbor the specific gene translocation or when there is small tumor volume (i.e. core biopsies). 10 However, there are limitations of FISH, which should be recognized to avoid diagnostic errors. FISH signals may be affected by cold ischemia time, time to fixation and tissue factors (e.g. abundance of collagen and extracellular matrix). 10 Acid-based decalcifying agents like formic or hydrochloric acid still widely used to process bone specimens, and lead to DNA and RNA degradation. 11, 12 In addition, unusual breakapart signal patterns (e.g. isolated 5 ′ or 3 ′ signals or increased copy number) and their significance have not been addressed in the way of standardized interpretation guidelines for individual probes. Similarly, selection of cutoffs to determine gene rearrangement or amplification varies among individual probes and laboratories.
Royal Prince Alfred Hospital (RPAH) is a tertiary referral center for the diagnosis and management of BST. We present our data with regard to a range of probes used in our department (MDM2, SS18, FUS, DDIT3, FUS, USP6, PDGFB, TFE3 and ALK) including specificity and sensitivity for a subset of those. The results for EWSR1 FISH will not be discussed in this manuscript, as these have been previously reported. 1 Although the diagnosis of BST tumors in our unit is exclusively performed by experienced BST pathologists, our cohort also includes external referral cases sent for consultation and a further proportion of cases exclusively sent for FISH performance without internal pathology review. For our internal cases, the final diagnosis was based on a consensus diagnosis of at least two expert BST pathologists (AM/RK/SM/FB/FR) taking into account the morphology, immunohistochemical findings, FISH results as well as the clinical and radiological correlation following discussion at a multidisciplinary meeting, as is standard practice in our institution. The selection criteria to perform FISH in our department are variable depending on individual entities.
MATERIALS AND METHODS
Overall, the general rules applied to determine which cases required (Table 1) . FISH for ALK was considered positive if the nuclei analyzed showed a split red and green signal at least two signal distances apart or loss of a 3 ′ green signal. MDM2:CEP12 ratio ≥2.0 was considered amplified. Sensitivity, specificity and positive predictive value (PPV) and negative predictive value (NPV) were calculated using the MedCalc statistical software tool.
Calculation of the sensitivity and specificity was performed based on the preferred histological diagnosis, which was made as previously TA B L E 1 Details of the FISH probes used in this study sensitivity and specificity is difficult to apply to diagnostic entities, which may potentially require more than one molecular technique such as RT-PCR or sequencing to confirm or exclude a specific gene alteration. As a limitation of this study, no further molecular tool is available in our department. More importantly, it is also difficult to determine the exact specificity and sensitivity of the diagnosis of BST neoplasms, as specific gene changes are not yet regarded as strictly required to make the diagnosis, as per the current WHO consensus. 7 This implies that bona fide examples of some translocation-associated sarcomas can potentially lack the specific translocation or more likely, appear undetected with the current technology.
RESULTS
After excluding 12 cases with undetectable FISH signals (eight bony specimens and four lipomatous tumors), FISH analysis was successfully performed on 575 interpretable BST specimens in our department from 2010 till November, 2015.
From the 575 specimens with adequate hybridization signals, 29
were comprised of bony specimens, all of which were subjected to EDTA-based decalcification (nine tested for MDM2, eight for SS18, four for FUS and eight for USP6). The remaining of the tissues tested corresponded to FFPE tissue with only one case derived from a cell block preparation, which was tested following the same protocol as described for tissues.
From this cohort, 135 cases were analyzed for EWSR1 FISH and this subset of cases has been previously published (please refer to reference 1). Therefore, these results will not be discussed. Six additional cases were excluded from this series, as the final histopathological diagnosis could not be confirmed, leaving 434 interpretable FISH assays on BST tumor samples for further analysis (Table 2) . MDM2 copy number probe was the commonest assay performed (n = 180), followed by SS18 (n = 97), FUS (n = 64), DDIT3 (n = 37), USP6 (n = 30), PDGFB (n = 13), TFE3 (n = 8) and ALK (n = 5). As described in Table 2 Mixoid LPS:
Myxoid LPS:
Nodular fasciitis:
LGFMS: n LGFMS, low-grade fibromyxoid sarcoma; SEF, sclerosing epithelioid fibrosarcoma; ABC, aneurysmal bone cyst; DFSPs, dermatofibrosarcoma protuberans; IMT, inflammatory myofibroblastic tumor; NOS, not otherwise specified; N/A, not applicable.
MDM2 copy number FISH
The vast majority of MDM2 amplified cases (n = 61; Figure 1A-C; FISH results was 17% (n = 31 of 180), which motivated a change in the diagnosis in 6% of all cases (n = 11). In our department, MDM2 FISH is the only modality used for the diagnosis, as MDM2 or CDK4 immunohistochemistry is not available.
Break-apart FISH probes
From the 97 cases tested for SS18, 36% (n = 35) were rearranged and 64% (n = 62) were nonrearranged (Figure 2G-H; Table 2 ). All the rearranged cases corresponded to monophasic or biphasic SSs (SSs; 100%).
For the cases lacking SS18 rearrangement, FISH was supportive of an alternative preferred diagnosis in 89% (55 of 62) of the cases, whereas in the remaining 11% (seven of 62), the absence of an SS18 rearrangement motivated a change in the diagnosis from SS to that of spindle cell sarcoma. Overall, in our institution, FISH for SS18 demonstrated 83%
and 100% sensitivity and specificity, respectively (PPV: 100%; NPV: 89%) and an overall histology and FISH discrepancy of 11% (seven of 97), resulting in a change in the diagnosis in 7% of the cases tested.
FISH for FUS and DDIT3 combined was performed in 101 cases ( Table 2 ). The most frequent utility of both probes was to support (Table 3) . Overall, the sensitivity and specificity in our department for FUS is 74% and 100%, respectively, and for DDIT3 is 100% and 92%. Table 2 ). ALK and TFE3 gene rearrangements were identified in three of four (80%) inflammatory myofibroblastic tumors (IMTs; Figure 2E -F) and in three of four alveolar soft part sarcomas (Figure 2I-J) , respectively. Although TFE3 FISH was also performed to support the diagnosis of PEComa in two additional cases, neither of those showed evidence of rearrangement. Due to the small number of cases tested for these probes, it is not possible to estimate the sensitivity and specificity for each probe or to draw further conclusions. 
TA B L E 3 Cohort of cases including low-grade fibromyxoid sarcomas (LG-
FMSs), sclerosing epithelioid fibrosarcomas (SEFs) and tumors with hybrid histopathological features
DISCUSSION
The use of FISH to detect characteristic gene rearrangement or copy number changes has been an invaluable tool to assist accurate diagnosis and treatment of patients with BSTs at our institution.
MDM2 FISH is a very useful tool in the classification of WDLs and
DDLs. Amplification of the MDM2 gene, among others (e.g. CDK4, DDIT3 and HMGA2), is the result of giant marker and ring chromosomes due to amplification of the 12q15 region. 33 MDM2 amplification, detected by FISH in our laboratory, showed a 80% and 97% sensitivity and specificity, respectively, in the classification of ALT/WDL and lipomas, which is similar to that reported in other published series (80-100%). 10, [34] [35] [36] Lack of concordance between histopathology and FISH usually occurs due to overestimation of cytological atypia within large lipomas, part of which is associated with the presence of fat necrosis. [35] [36] [37] [38] The presence of fat necrosis in our series accounted for the reclassification of four of eight lipomatous lesions (from ALT/WDL to lipoma). In our series, MDM2 FISH supported the diagnosis in 80% of the cases with the preferred clinicopathological diagnosis of DDL (20 of 25). There is now evidence that indicates that distinction between undifferentiated pleomorphic sarcomas (UPSs) and DDLS should be performed based on MDM2 FISH as DDLPs present a more favorable prognosis than UPSs. [39] [40] [41] [42] Additionally, the potential use of MDM2 therapeutic targets such as nutlin-3a might provide benefit in this group of patients. 40 In agreement with other studies, 23, 34, 36, [42] [43] [44] we observed that DDLs showed a higher level of MDM2 copy number when compared with WDL/ALTs (10.5 vs 7.7, respectively) but this is not statistically significant and it has no prognostic or predictive value as discussed in those previous studies. Interestingly, MDM2 amplification levels might play a role in tumor dedifferentiation and tumor progression. 22, 23, 45 MDM2 amplification is also identified in a proportion of other sarcoma types and for example in low-grade central and parosteal osteosarcomas (including those undergoing dedifferentiation). 21, 27, 40, 46 In our cohort, only 33% (three of nine) of low-grade (central and parosteal) osteosarcomas were MDM2
amplified. It is likely that variability in the decalcification process in a proportion of our referral cases contributed to the decreased FISH detection rate, as acid-based products cause DNA hydrolysis. 46 EDTA-based decalcification protocols should be followed in the processing of bone specimens. 46 MDM2 amplification is also reported in intimal sarcoma, and in a small proportion of other BST entities such as MPNST and leiomyosarcomas.
In our institution, FISH for SS18 demonstrated 83% and 100% sensitivity and specificity, respectively, in the diagnosis of SS. From the 97 cases tested, 100% of the rearranged cases corresponded to SSs, whereas discrepancies between FISH and the preferred clinicopathological diagnosis (n = 11) motivated a change in the diagnosis of SS to that of undifferentiated spindle cell sarcoma in 7% (n = 7) of the cases.
SS comprises approximately 10% of soft tissue sarcomas and over 90% of the cases are characterized by the t(X;18)(p11.2;q11.2) translocation. Similar to our series, FISH has demonstrated >80% sensitivity in the diagnosis of SS when compared with RT-PCR. 13, 47, 48 We ALK gene fusions were identified in three of four (75%) IMTs. This frequency is higher than the expected frequency of ALK rearrangements in IMTs (50%), but the sample size is too small to draw conclusions.
FUS or EWSR1 gene rearrangements were highly predictive of the diagnosis of LG-FMS or SEF (or hybrid tumors), respectively, when MUC4 immunostaining was also identified ( SEFs was consistent with that reported in the literature. 8, 14, 32 In this study, we confirm that FISH to detect amplification or structural rearrangements is an important ancillary tool in the accurate diagnosis of BST tumors. However, it is essential that the FISH result not be used as an isolated test, but must be evaluated in the con- ing the underlying changes in challenging cases. 56 Although FISH and other molecular tests applied to tissue diagnosis pose an additional cost to patients and institutions, it increases the rate of accurate diagnoses leading to cost benefits in the long term. 57 In this study, we saw a change in diagnosis based on FISH in 7% using SS18 and 6% of lipomatous lesions using MDM2 (benign to malignant or vice versa). In addition, the identification of neoplasms with specific driving genetic events may provide a further cost-benefit for subsets of patients, who might be potential candidates for continuously emerging therapeutic targets.
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